Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.

Buchler T, Pavlik T, Bortlicek Z, Poprach A, Vyzula R, Abrahamova J, Melichar B.

Med Oncol. 2012 Dec;29(5):3321-4. doi: 10.1007/s12032-012-0293-x. Epub 2012 Jun 30.

PMID:
22752573
2.

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.

Miyake H, Kusuda Y, Harada K, Sakai I, Fujisawa M.

Int J Clin Oncol. 2013 Feb;18(1):81-6. doi: 10.1007/s10147-011-0347-7. Epub 2011 Nov 18.

PMID:
22095244
3.

Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?

Calvani N, Morelli F, Leo S, Orlando L, Lombardi L, Gnoni A, Cinefra M, Maiello E, Lorusso V, Cinieri S.

Med Oncol. 2012 Sep;29(3):1908-13. doi: 10.1007/s12032-011-0048-0. Epub 2011 Aug 20.

PMID:
21858552
4.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.

5.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

PMID:
23548259
6.

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8.

PMID:
24321257
7.

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.

Eur Urol. 2008 Dec;54(6):1373-8. doi: 10.1016/j.eururo.2008.07.051. Epub 2008 Aug 8.

PMID:
18692304
8.

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.

Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.

BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23.

9.

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

Levy A, Menard J, Albiges L, Loriot Y, Di Palma M, Fizazi K, Escudier B.

Eur J Cancer. 2013 May;49(8):1898-904. doi: 10.1016/j.ejca.2013.02.003. Epub 2013 Mar 13.

PMID:
23490648
10.

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.

Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J.

Ann Oncol. 2012 Feb;23(2):395-401. doi: 10.1093/annonc/mdr065. Epub 2011 May 2.

11.

Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.

Biondani P, Verzoni E, Torri V, Porcu L, Grassi P, Testa I, DE Braud F, Procopio G.

Anticancer Res. 2014 May;34(5):2395-8.

PMID:
24778049
12.
13.

Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?

Calvani N, Morelli F, Chiuri V, Gnoni A, Scavelli C, Fedele P, Orlando L, Maiello E, Lorusso V, Cinieri S.

Med Oncol. 2013;30(2):578. doi: 10.1007/s12032-013-0578-8. Epub 2013 Apr 24.

PMID:
23613183
14.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ.

J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.

15.

Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.

Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P, Dimopoulos M, Papazisis K.

Med Oncol. 2012 Jun;29(2):750-4. doi: 10.1007/s12032-010-9815-6. Epub 2011 Jan 30.

PMID:
21279702
16.

[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].

Latteux G, Lebdai S, Hoarau N, Abadie-Lacourtoisie S, Delva R, Chautard D, Azzouzi AR, Bigot P.

Prog Urol. 2013 Mar;23(3):184-94. doi: 10.1016/j.purol.2012.09.014. Epub 2012 Oct 25. French.

PMID:
23446283
17.

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.

Ambring A, Björholt I, Lesén E, Stierner U, Odén A.

Med Oncol. 2013 Mar;30(1):331. doi: 10.1007/s12032-012-0331-8. Epub 2012 Dec 18.

18.

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

Koo DH, Park I, Ahn JH, Lee DH, You D, Jeong IG, Song C, Hong B, Hong JH, Ahn H, Lee JL.

Cancer Chemother Pharmacol. 2016 Feb;77(2):339-47. doi: 10.1007/s00280-015-2942-1. Epub 2015 Dec 21.

PMID:
26687171
19.

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group.

Ann Oncol. 2012 Dec;23(12):3137-43. doi: 10.1093/annonc/mds145. Epub 2012 Jun 13.

20.

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.

Cancer. 2009 Jan 1;115(1):61-7. doi: 10.1002/cncr.24009.

Items per page

Supplemental Content

Write to the Help Desk